Biofrontera Receives FDA Approval for Ameluz Skin Cancer Treatment Amid Liquidity Concerns
Biofrontera (BFRI) has achieved a significant regulatory milestone with the FDA approval of its topical gel, Ameluz, for treating superficial basal cell carcinoma. This second indication allows the company to expand its market reach within dermatology clinics using its existing commercial infrastructure and installed base of 853 light devices. Despite strong revenue growth—with third-quarter product revenue rising 30% year-over-year to $9.1 million—the company faces serious financial headwinds. Biofrontera reported a decline in cash reserves to $3.2 million as of September 30, 2026, leading management to issue a 'going concern' warning regarding its ability to sustain operations for the next 12 months. To stabilize its position, the company is working to resolve previous import hurdles via U.S. Customs clearance for its redesigned RhodoLED XLC lamp and plans to utilize a line of credit and upcoming milestone payments to manage liquidity.

Tickers: $BFAGY.CNV
Topics: FDA approval Q3 earnings Revenue growth Skin cancer treatment